In a note issued Thursday morning, Bank of America analyst, Bob Hopkins reinstated coverage of Medtronic, Inc. MDT with a Buy rating and a $75 price objective.
Hopkins explained the reason driving the Buy rating is Medtronic's proposed acquisition of Covidien plc COV, which he expects to close with in the next three to four months and is modeling a January 1st close date.
Hopkins wrote, "Based on our estimates, the proposed deal for COV would be accretive to earnings within a year of completion, should allow MDT to drive double-digit EPS growth for the next several years, would lower MDT's risk profile, better positions the company to win in the new HC environment and would give MDT greater financial flexibility by providing them access to COV's global cash."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in